National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Lanadelumab (Takhzyro®)

Lanadelumab (Takhzyro®) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.

NCPE Assessment Process Complete
Rapid review commissioned 19/03/2019
Rapid review completed 23/05/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of lanadelumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/05/2019
Pre-submission consultation with Applicant 20/06/2019
Submission received from Applicant 04/10/2019
Preliminary review sent to Applicant 14/02/2020
NCPE assessment re-commenced 13/03/2020
Factual accuracy check sent to Applicant 22/05/2020
NCPE assessment re-commenced 03/06/2020
NCPE assessment complete 26/06/2020
Current status The NCPE recommends that lanadelumab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.